China Biologic Products, Inc. - Exhibit 10.1 - Filed by
   newsfilecorp.com






Exhibit 10.1

Equity Transfer Agreement 

This equity transfer agreement is entered into as of July 8,
2010 in Tai’an, Shandong Province, by and between the following parties: 

Transferee: Logic Management Consulting (China) Co., Ltd.
(hereinafter “Transferee”) 

Address: 2nd floor of the Comprehensive Building of
Xinghuo Technology Park, Zhongtianmen Street, High-tech industry District,
Tai’an, Shandong Province, PRC 

Legal Representative: Tung Lam           Title: Chairman of the Board of
Directors 

Transferor: Shandong Taibang Biological Product Co., Ltd. (PRC)
(hereinafter “Transferor”) 

Address: No.14 Hushan E. Road, Tai’an,
Shandong Province 

Representative: Tung Lam Title: CEO 

Whereas: 

	1. 	
      Shandong Taibang Medical Co., Ltd. (hereinafter
      “Taibang Medical” or “Subject Equity
      Interests”) is a foreign-invested limited liability company duly
      established in accordance with PRC laws and lawfully existing. Its
      Business License Number is 370900018022068 and its registered capital is
      fully received as of the date of this Agreement. 

	 	
       

	2. 	
      Transferee is a limited liability company established in
      accordance with PRC laws, which holds no equity interest in Taibang
      Medical as of the date of this Agreement. 

	 	
       

	3. 	
      Transferor is a limited liability company established in
      accordance with PRC laws, which holds 100% equity interest in Taibang
      Medical. 

	 	
       

	4. 	
      Transferor hereby agrees to transfer Subject Equity
      Interests to Transferee according to the terms and conditions of this
      Agreement, and Transferee agrees to accept the Subject Equity Interests
      according to the terms and conditions of this Agreement.




NOW THEREFORE, upon mutual agreement, Transferee and Transferor
hereby execute this Equity Transfer Agreement through the following stipulations
to be complied with: 

Article 1 Definition 

	1.1 	The nouns and terminologies have the following meanings in this
      Agreement, except for the otherwise defined: 






	 	(1) 	
      “This Agreement” means this Equity Transfer Agreement
      including any written amendment, revision or deletion agreed between both
      parties and approved by relevant authorities. 

	 	 	
       

	 	(2) 	
      “Working day” means days other than Sunday, Saturday,
      legal holiday and public holiday in PRC. 

	 	 	
       

	 	(3) 	
      “The Closing day” means the day on which all the Subject
      Equity Interests have been transferred to the Transferee and the
      alteration registration formalities with AIC are completed for the equity
      interests transfer. 

	 	 	
       

	 	(4) 	
      “Year, month, day” means Calendar year, month, day,
      except when otherwise defined in this Agreement. 

	 	 	
       

	 	(5) 	
      “Transfer price” means the consideration paid by
      Transferee to Transferor for obtaining the Subject equity interests under
      the provisions of this Agreement. 

	 	 	
       

	 	(6) 	
      “Subject Equity Interests” means the 100% equity interest
      in Taibang Medical that Transferor transfers to Transferee according to
      the clauses and conditions of this Agreement. 



1.2 General Paraphrase 

The paraphrase of this Agreement is processed as follows,
except for those otherwise required: 

	 	(1) 	The name of the title of each chapter is only for reference in this
      Agreement. It does not compose part of this Agreement and does not assist
      in any paraphrase in this Agreement. 
	 	 	 
	 	(2) 	The amounts referred to in this Agreement are all in Renminbi, unless
      otherwise indicated. 


Article 2 Equity Transfer Price and Payment


	2.1 	
      The two parties have agreed after negotiation, that
      Transferor transfers the Subject Equity Interests to Transferee and
      Transferee accepts the Subject Equity Interests and pays the transfer
      price accordingly, in compliance with the prerequisites set in Article 3
      of this Agreement and other restrictive terms and conditions of this
      Agreement. 

	 	
       

	2.2 	
      Transferee and Transferor determined after negotiation
      that the Transfer Price is RMB6,440,000 (the “Transfer Price”). 

	 	
       

	2.3 	
      The Transferee shall, within 60 days after the updated
      business license is obtained, pay the Transfer Price to the Transferor in
      RMB. Meanwhile, Transferor shall designate and notify to Transferee its
      receipt account at least ten days in advance. 







Article 3 Prerequisites 

	3.1 	The two parties agree that the success of the equity
      transfer under this Agreement and the payment of the transfer price depend
      on the full satisfaction of the following prerequisites:




	 	3.1.1 	
      The Subject Interest transfer has been approved through
      obtaining more than two-thirds votes in favor of the transfer of the
      Subject Equity Interests by the Board of directors of Taibang Medical.
    

	 	 	
       

	 	3.1.2 	
      All necessary documents, such as approval, consents and
      permits, for the completion of the transaction under this Agreement, have
      been obtained, including but not limited to approval from the Bureau of
      Commerce and other authorities, the certificate of approval for
      foreign-invested enterprises, and the registration modification by the
      Administration for Industry and Commerce for Taibang Medical. 

	 	 	
       

	 	3.1.3 	
      The declaration, commitment and guarantee made by all
      parties in Article 5 of this Agreement is true, accurate and effective
      until the closing day. 




	3.2 	The two parties agree that each of them shall make all efforts to
      complete the above prerequisites. 


Article 4Closing and Transition 

	4.1 	
      Transferor shall give the following documents to
      Transferee on or before the closing day: the approval from the Bureau of
      Commerce for the equity transfer under this Agreement and the registration
      modification documents in China’s Administration for Industry and
      Commerce. 



Article 5 Declaration, Guarantee and Commitment


	5.1 	
      Transferee makes the following statement, commitment and
      guarantee to Transferor unconditionally and irrevocably.





	 	5.1.1 	
      Transferee is an independent legal entity established in
      accordance with Chinese laws and validly existing, and has full capacity
      and authority to enter into this Agreement and to exercise its rights and
      perform its obligations in accordance with this Agreement. 

	 	 	
       

	 	5.1.2 	
      Transferee enters into this Agreement and exercises its
      rights and performs its obligations accordingly, and shall not violate.
      




	 	5.1.2.1 	
      any laws Transferee shall comply with. 

	 	 	
       

	 	5.1.2.2 	
      any document or article as the basis of Transferee’s
      establishment and/or any document that imposes effective restriction on
      Transferee. 




	 	5.1.3 	Transferee has never, until the date of this Agreement, signed as a
      signatory party on any document or agreement that imposes restriction on or
      prohibits Transferee from entering into this Agreement or exercising its
      right or performing its obligation as stipulated in this Agreement. 







	 	5.1.4 	
      Transferee has obtained all proper authorization, permits
      and approvals on signing this Agreement and performing and completing the
      transactions under this Agreement. 

	 	 	
       

	 	5.1.5 	
      This Agreement constitutes a valid, binding and
      executable document to Transferee, and all statements made by Transferee
      in this Agreement are true, accurate and complete.





	5.2 	Transferor makes the following statements, commitments and guarantees
      to Transferee unconditionally and irrevocably: 



	 	5.2.1 	
      Transferor is a limited liability company established in
      accordance with PRC laws and validly existing, and has full capacity and
      authority to enter into this Agreement and to exercise its rights and
      perform its obligations in accordance with this Agreement. 

	 	 	
       

	 	5.2.2 	
      Transferor enters into this Agreement and exercises its
      rights and performs its obligations under this Agreement, and shall not
      violate any laws and regulations that Transferor shall comply with.
  

	 	 	
       

	 	5.2.3 	
      Transferor has never, until the date of this Agreement,
      signed as a signatory party on any document or agreement that imposes
      restriction on or prohibits Transferor from entering into this Agreement
      or exercising its right or performing its obligation as stipulated in this
      Agreement. 

	 	 	
       

	 	5.2.4 	
      Transferor has obtained all proper authorization, permits
      and approvals on signing this Agreement and performing and completing the
      transactions under this Agreement. 

	 	 	
       

	 	5.2.5 	
      This Agreement constitutes a valid, binding and
      executable document to Transferor, and all statements made by Transferor
      in this Agreement are true, accurate and complete.





	 	5.2.6 	
      The Transferor holds lawful titles to the Subject Equity
      Interests, and the Subject Equity Interests are not subject to any
      restrictions from mortgages, liens or any other rights from third parties
      except that the transaction under this Agreement shall be approved by
      relevant authorities. 



Article 6 Liability for Breach 

	6.1 	
      Any party that does not appropriately or completely
      perform any or all obligations under this Agreement will be regarded as
      being in breach hereof. The non-breaching party is entitled to terminate
      this Agreement promptly and to require the breaching party to compensate
      the non-breaching party for its losses. 

	 	
       

	6.2 	
      The modification or rescission of this Agreement does not
      affect the right of the non-breaching party to ask for compensation from the breaching party. 







Article 7 Force Majeure 

	7.1 	
      “Force Majeure” herein means any events which could not
      be foreseen, avoided or overcome, and the impact of the events cannot be
      eliminated through reasonable efforts and expenses, including but not
      limited to, earthquake, typhoon, flood, fire, war, or other events
      recognized by the international business practice. 

	 	
       

	7.2 	
      Either party that has been prevented by force majeure
      from fully or partially performing its obligations hereunder is suspended
      from performing the foregoing obligations. The suspension period will last
      as long as the force majeure event lasts. 

	 	
       

	7.3 	
      The party that has been affected by the force majeure
      event and has suspended its obligations performance shall, within the
      shortest period of time, notify the other party the force majeure event in
      written form, and shall, within 15 days of the occurrence of the force
      majeure event, provide to the other party by express or air mail the
      proper proof of the occurrence and the probable duration of the force
      majeure event. The party which issues the notice shall use its best
      efforts to mitigate the impact and losses caused by the force majeure.
    

	 	
       

	7.4 	
      Transferor and Transferee shall, after occurrence of the
      force majeure event, determine promptly the subsequent procedure of
      implementation of this Agreement through friendly negotiation. The
      obligations of both parties under this Agreement shall be resumed after
      the vanishing of the force majeure event or the influence of the force
      majeure event. 



Article 8 Confidentiality 

	8.1 	
      Transferor and Transferee shall keep confidential all the
      information that comes into the knowledge of Transferor and Transferee
      during this equity transfer Agreement, including but not limited to:
    




	 	8.1.1 	all terms and conditions in this Agreement, 
	 	 	 
	 	8.1.2 	negotiations related to this Agreement, 
	 	 	 
	 	8.1.3 	the subject of this Agreement, 
	 	 	 
	 	8.1.4 	Business secrets of both Transferor and Transferee,



except for the disclosure according to
term 8.2 in this Agreement. 

	8.2 	Only under the following circumstances, the information in the term
      8.1 could be disclosed by Transferor and Transferee




	 	8.2.1 	under legal requirements, 







	 	8.2.2 	
      under the requirement of any competent government
      authority, regulatory body or stock exchange committee, 

	 	 	
       

	 	8.2.3 	
      disclosure is made to Transferor or Transferee’s own
      professional consultants (including but not limited to lawyers). However,
      the party that makes such disclosure shall bear joint confidentiality
      obligations with its professional consultants, 

	 	 	
       

	 	8.2.4 	
      information of this Agreement is known by the public not
      due to the fault of Transferor or Transferee, 

	 	 	
       

	 	8.2.5 	
      written consent is made by both Transferor and Transferee
      in advance. 




	8.3 	Even if the transaction under this Agreement is not completed due to
      any reason, Transferor and Transferee shall comply with this
      confidentiality clause. 
	 	 
	8.4 	Transferor and Transferee shall comply with this confidentiality
      clause even after this Agreement is completed, without time limitation.
  


Article 9 Applicable Laws and Settlement of
Disputes 

	9.1  	
      The execution, effectiveness, interpretation and
      performance of this Agreement and the settlement of any disputes arising
      from the transaction under this Agreement shall be governed by the laws of
      the PRC issued publicly. 

	 	
       

	9.2  	
      Any dispute arising out of or related to this Agreement
      shall be settled by friendly negotiation by both parties hereby. If no
      resolution is attained through friendly negotiation within 30 days after
      the dispute arises, any party may bring a legal action at the China
      International Trade Arbitration Commission. The arbitration decision is
      final and binding upon all parties in the disputes. The arbitration fee
      shall be paid by the loser unless otherwise specified. And during the
      arbitration process, except for the part in dispute and under arbitration,
      this Agreement shall continue to be implemented. 



Article 10 Effectiveness and other terms


	10.1 	
      This Agreement is effective after the legal
      representatives or authorized representatives of both Transferor and
      Transferee sign on this Agreement and the official seal of both Transferor
      and Transferee is chopped on this Agreement, and also upon approval by the
      relevant government authority. 

	 	
       

	10.2 	
      This Agreement will be made in six counterparts with
      Transferor and Transferee each holding one and the other copies given to
      Taibang Medical and submitted to the relevant government authorities.
    

	 	
       

	10.3 	
      The rights, obligations or liabilities under this
      Agreement are not transferable unless agreed by both









		Transferor and Transferee. 
	 	 
	10.4 	
      Modification or supplementation on this Agreement is
      effective only when a written document is signed between Transferor and
      Transferee after negotiation. Any written supplemental document and
      appendix to this Agreement is deemed to be inseparable part of this
      Agreement and has equal legal force with this Agreement. 

	 	
       

	10.5 	
      The transaction charges arising from the execution of
      this Agreement will be paid by the Transferor and Transferee respectively
      

	 	
       

	10.6 	
      This Agreement is officially signed by both parties on
      the date recorded on the first page of this Agreement.




(End of the main text) 




The page for signature 

(No text, only signature page for the Equity Transfer
Agreement) 

Transferee: Logic management consulting (china) Co., Ltd. 

Legal representative or Authorized representative: 

/s/ Tung Lam 

Transferor: Shandong Taibang Biological Products Co., Ltd.
(PRC) 

Legal representative or Authorized representative: 

/s/ Tung Lam 

July 8, 2010